Benjamin Edwards Inc Recursion Pharmaceuticals, Inc. Transaction History
Benjamin Edwards Inc
- $8.36 Billion
- Q3 2025
A detailed history of Benjamin Edwards Inc transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Benjamin Edwards Inc holds 143,164 shares of RXRX stock, worth $778,812. This represents 0.01% of its overall portfolio holdings.
Number of Shares
143,164
Previous 164,776
13.12%
Holding current value
$778,812
Previous $833,000
16.21%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding RXRX
# of Institutions
365Shares Held
289MCall Options Held
7.75MPut Options Held
6.1M-
Vanguard Group Inc Valley Forge, PA36.1MShares$196 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl33MShares$179 Million1.38% of portfolio
-
Baillie Gifford & CO24MShares$130 Million0.09% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$94.2 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$79.8 Million0.31% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $982M
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...